Search academic texts

Information × Registration Number 0220U104888, 0118U007363 , R & D reports Title To work out the technology for the treatment of neutrophil bronchial asthma and bronchial asthma associated with chronic obstructive pulmonary disease оn the background of their endotypes popup.stage_title Head Yashyna Liudmyla O, д.мед.н. Registration Date 30-12-2020 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2  Object - 30 steroid-naive patients with asthma combined with COPD with neutrophilic inflammation. Based on a study of inflammatory markers and pulmonary function indices, 30 steroid-naive patients with bronchial asthma (BA) combined with chronic obstructive pulmonary disease (COPD) with neutrophilic inflammation were identified. Characteristic features of patients with this endotype are uncontrolled course of the disease (ACT (15,8  0,5) points, ACQ (2,3  0,1) points, mMRC (2,3  0,1) points and CAT 18,2  1,0) points), mainly infectious-allergic nature of exacerbations, which treatment requires the use of antibacterial therapy. The most common comorbidities in patients with neutrophilic asthma are allergic rhinitis in 23,3 % of patients, polyposis ethmoiditis in 16,7 %, allergic skin diseases in 20,0 %, obesity in 26,7 %, cardiovascular diseases in 23,3 %, arthritis in 13,3 % of patients. In 40,0 % of patients there are symptoms of mild and moderate depression, and in 16,7 % of patients - severe drowsiness and sleep apnea. The technology of using the combined drug budesonide / formoterol in basic therapy in steroid-naive patients with bronchial asthma combined with chronic obstructive pulmonary disease with neutrophilic inflammation, which allows to achieve clinical and functional efficacy in 93,3 % of patients, which is 20,0 % exceeds the effectiveness of treatment with montelukast with formoterol. A new method of treatment of patients with bronchial asthma with neutrophilic type of inflammation has been developed, it’s use allows to achieve clinical and functional efficiency in 93,3 % of patients, improving control of asthma symptoms and reducing exacerbations, improving bronchial patency at the level of small bronchi and reducing fixed bronchial obstruction, exercise capacity. Sphere of application - therapy, pulmonology, allergology. Product Description popup.authors Ignatieva Victoria I Humeniuk Halyna L Zvol Inna V Moskalenko Svitlana M Opimakh Svitlana G Parkhomenko Nataliya V Polyanska Maryna O Prymushko Nataliya A Simonov Serhiy S Feshchenko Yurii I Yashyna Liudmyla O popup.nrat_date 2020-12-30 Close